|
180 Life Sciences Corp (NASDAQ: ATNF) |
|
180 Life Sciences Corp
ATNF's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
180 Life Sciences's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.73 %
180 Life Sciences net loss decreased from $-4 millions, to $-1 millions in III. Quarter 2024,
• More on ATNF's Growth
|
|
180 Life Sciences realized a net loss in trailing twelve months.
180 Life Sciences realized cash reduction of $ -1.15 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.
• More on ATNF's Valuation
|
|
|
|
|
180 Life Sciences realized net loss in trailing twelve months.
180 Life Sciences realized cash outflow of $ -1.15per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.
180 Life Sciences Price to Book Ratio is at 0.58 lower than Industry Avg. of 79.2. and higher than S&P 500 Avg. of 0.01
• More on ATNF's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com